Pfizer Prevails in Accupril Patent Suit
Main Category: Public HealthArticle Date: 30 Jun 2004 - 24:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Pfizer, Inc said today it has prevailed in a patent infringement suit in which Teva Pharmaceuticals USA Inc. (Teva), was seeking approval to sell a generic version of Pfizer's blood pressure medicine Accupril (quinapril hydrochloride).
In a June 29 decision, Judge Dickinson R. Debevoise of the United States District Court for the District of New Jersey held that Warner-Lambert's patent on a stable formulation of quinapril (U.S. 4,743,450), was valid, infringed and enforceable against Teva. The decision affirmed the court's previous findings of infringement and validity. The court also rejected Teva's allegations that Warner-Lambert had committed inequitable conduct in obtaining the patent.
Further, the court issued an injunction blocking the approval of Teva's drug application until the February 2007 expiration of the patent.
"Pfizer is very pleased with the court's decision because it affirms positions the company has maintained with respect to the Accupril patent from the very beginning of the litigation," said Jeff Kindler, Pfizer executive vice president and general counsel. "Pfizer will continue to aggressively defend challenges to its intellectual property."
Judge Debevoise also ruled that Pfizer's victory in the patent case removed any reason to allow Teva to assert antitrust violations against Pfizer and Warner-Lambert. The judge denied as futile Teva's motion in this regard.
In another legal decision involving Accupril, Pfizer earlier this week successfully obtained dismissal without prejudice of a declaratory action filed by another generic company, Apotex Inc., against the Accupril formulation patent.
Visit our public health section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/10156.php>
APA
http://www.medicalnewstoday.com/releases/10156.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





